

AMICUS THERAPEUTICS INC

Form 3

May 30, 2007

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB  
Number: 3235-0104Expires: January 31,  
2005Estimated average  
burden hours per  
response... 0.5**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

FHM IV LP

(Last)

(First)

(Middle)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

05/30/2007

3. Issuer Name **and** Ticker or Trading Symbol

AMICUS THERAPEUTICS INC [FOLD]

4. Relationship of Reporting  
Person(s) to Issuer5. If Amendment, Date Original  
Filed(Month/Day/Year)

(Check all applicable)

\_\_\_\_ Director    ☒ 10% Owner  
\_\_\_\_ Officer    \_\_\_\_ Other  
(give title below)    (specify below)

6. Individual or Joint/Group  
Filing(Check Applicable Line)  
\_\_\_\_ Form filed by One Reporting  
Person  
\_X\_ Form filed by More than One  
Reporting Person

TWO UNION SQUARE, 601  
UNION STREET STE 3200

(Street)

SEATTLE, WA 98101

(City)

(State)

(Zip)

**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)Date  
ExercisableExpiration  
Date3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)

Title

Amount or  
Number of  
Shares4. Conversion  
or Exercise  
Price of  
Derivative  
Security5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect  
(I)6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

(Instr. 5)

|                                             |       |       |                                      |           |          |       |                              |
|---------------------------------------------|-------|-------|--------------------------------------|-----------|----------|-------|------------------------------|
| Series B Convertible Preferred Stock        | Â (1) | Â (1) | Common Stock                         | 988,446   | \$ (1)   | I (2) | By Frazier Healthcare IV, LP |
| Series B Convertible Preferred Stock        | Â (1) | Â (1) | Common Stock                         | 5,016     | \$ (1)   | I (2) | By Frazier Affiliates IV, LP |
| Series C Convertible Preferred stock        | Â (1) | Â (1) | Common Stock                         | 1,011,088 | \$ (1)   | I (2) | By Frazier Healthcare IV, LP |
| Series C Convertible Preferred Stock        | Â (1) | Â (1) | Common Stock                         | 5,132     | \$ (1)   | I (2) | By Frazier Affiliates IV, LP |
| Series D Convertible Preferred Stock        | Â (1) | Â (1) | Common Stock                         | 572,310   | \$ (1)   | I (2) | By Frazier Healthcare IV, LP |
| Series D Convertible Preferred stock        | Â (1) | Â (1) | Common Stock                         | 2,904     | \$ (1)   | I (2) | By Frazier Affiliates IV, LP |
| Warrant to purchase Series B (right to buy) | Â (3) | Â (3) | Series B Convertible Preferred Stock | 15,042    | \$ 6.375 | I (2) | By Frazier Healthcare IV, LP |
| Warrant to purchase Series B (right to buy) | Â (3) | Â (3) | Series B Convertible Preferred Stock | 76        | \$ 6.375 | I (2) | By Frazier Affiliates IV, LP |

## Reporting Owners

| Reporting Owner Name / Address                                                  | Relationships |           |         |       |
|---------------------------------------------------------------------------------|---------------|-----------|---------|-------|
|                                                                                 | Director      | 10% Owner | Officer | Other |
| FHM IV LP<br>TWO UNION SQUARE<br>601 UNION STREET STE 3200<br>SEATTLE, WA 98101 | Â             | Â X       | Â       | Â     |
| FRAZIER HEALTHCARE IV LP<br>Â                                                   | Â             | Â X       | Â       | Â     |
| FRAZIER AFFILIATES IV LP<br>Â                                                   | Â             | Â X       | Â       | Â     |

## Signatures

FHM IV, LP By: FHM IV, LLC, its General Partner /s/ Thomas S. Hodge, Chief Operating Officer

05/30/2007

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Issuer's Series B, Series C and Series D convertible preferred stock will automatically be converted into Common Stock, 1-for-1, upon the closing of the Issuer's initial public offering.

These securities are owned directly by the entity listed. Frazier Healthcare IV, LP and Frazier Affiliates IV, LP, are joint filers. FHM IV,

- (2) LP, the designated filer, serves as the general partner of Frazier Healthcare IV, LP and Frazier Affiliates IV, LP. FHM IV, LP disclaims beneficial ownership of the reported securities, except to the extent of its proportionate pecuniary interest therein.

Warrant to purchase Series B convertible preferred stock will automatically be exercised for cash immediately prior to the closing of the

- (3) Issuer's initial public offering. The Series B shares will automatically be converted to Common Stock upon the closing of the initial public offering.

Â

### Remarks:

ExhibitÂ 99.1Â Â JointÂ FilerÂ Information

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.